Levofloxacin-Resistant<i>Haemophilus influenzae</i>, Taiwan, 2004–2010

Kuo, Shu‐Chen; Chen, Pei-Chen; Shiau, Yih-Ru; Wang, Huiying; Lai, I Jui-Fen; Huang, Wei‐Chieh; Lauderdale, Tsai‐Ling

doi:10.3201/eid2008.140341

Cited by 48 publications

(48 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Although we found six small clusters, the majority of the strains were isolated from patients who had no relationship to each other. In a recent publication from Taiwan, regional clonal emergence was found in different areas of the country (35). None of the STs published in Taiwan were found in our study, suggesting that the evolution of FQresistant strains is regional (35).…”

Section: Discussioncontrasting

confidence: 53%

See 1 more Smart Citation

Molecular Characterization of Fluoroquinolone Resistance in Nontypeable Haemophilus influenzae Clinical Isolates

Puig

Tirado-Vélez

Calatayud

et al. 2015

Antimicrob Agents Chemother

View full text Add to dashboard Cite

Section: Discussioncontrasting

confidence: 53%

“…A recent surveillance study published in Taiwan showed a major increase in LVX resistance from 2% in 2004 to 24.3% in 2010 (35). In the United States in 2006, the percentage of FQ resistance was 0.1% (36), similar to the percentage found in Spain in 2011 (0.2%) (17).…”

Section: Discussionmentioning

confidence: 59%

Molecular Characterization of Fluoroquinolone Resistance in Nontypeable Haemophilus influenzae Clinical Isolates

Puig

Tirado-Vélez

Calatayud

et al. 2015

Antimicrob Agents Chemother

View full text Add to dashboard Cite

“…Furthermore, the prevalence of BLNAR, BLPAR, and BLPACR were 62.4, 6.1, and 4.1% in other Japanese study [17]. The rate of levofloxacin-resistant was 24.3% in another Japanese report [18]. In South Korea, the rate of BLNAR, BLPAR, and BLPACR were 40.2, 9, and 24.6 [19].…”

Section: Discussionmentioning

confidence: 81%

Clinical Characteristics of Haemophilus influenzae at General Hospital in the Central Region of Japan

Minami¹,

Sakakibara²,

Imura³

et al. 2016

JBM

View full text Add to dashboard Cite

Haemophilus influenzae is an important pathogen that caused several infection diseases, such as sinusitis, otitis media, sepsis, and meningitis. This study was conducted to find out the prevalence and antimicrobial susceptibility pattern of Haemophilus influenzae isolates at general hospital in the central region of Japan from December 2015 to January 2016. Haemophilus influenzae was identified by standard laboratory procedure. Antimicrobial susceptibility testing was performed by micro dilution assay according to CLSI recommendation. One hundred ninety-one Haemophilus influenzae were isolated, among which 95 (49.7%) were from male and 96 (50.3%) were from female. The age incidence of (0) years, (≤2) years, (≤5) years, and (6≤) years groups were 22(11.5%), 92(48.2%), 61(31.9%), and 16(8.4%), respectively. Positive samples were received mostly from the nasal discharge (177/92.7%), sputum (6/3.1%), tonsillar (6/3.1%), and pharynx (2/1.0%). Ceftriaxone was the most active antibiotics with 100% susceptible rates, followed by ciprofloxacin (99.5%) and minocycline (99%) in our study. Furthermore, we categorized four patterns: beta lactamase-negative ampicillin-sensitive strain (BLNAS), beta lactamase-negative ampicillin-resistant strain (BLNAR), beta lactamase-positive ampicillin resistant strain (BLPAR), and beta lactamase-positive amoxicillin-clavulanic acid-resistant strain (BLPACR) from those ampicillin susceptible results. The numbers of female were significant greater than those of male in BLPAR (p = 0.0336). With respect to antimicrobial susceptible pattern, there was no minocycline and piperacillin resistant strain in both BLNAS and BLNAR (p < 0.0001). Haemophilus influenzae infection spreads worldwide and inadequate use of antibiotics contributes to uptake of their new antimicrobial resistance. Continuous antimicrobial surveys are need for control the emergence and spread of antimicrobial resistance to reduce the morbidity and mortality.

show abstract

“…Other species, such as Haemophilus spp. and ␤-hemolytic streptococci, have been less prone to becoming fluoroquinolone nonsusceptible but are emerging at high rates in some countries (25)(26)(27)(28)(29)(30)(31). Hampering the advancement of fluoroquinolones to include other more potent agents has been difficult, due to the safety profile observed for this class.…”

Section: Discussionmentioning

confidence: 99%

In Vitro Activity of AZD0914, a Novel Bacterial DNA Gyrase/Topoisomerase IV Inhibitor, against Clinically Relevant Gram-Positive and Fastidious Gram-Negative Pathogens

Biedenbach¹,

Huband

Hackel³

et al. 2015

Antimicrob Agents Chemother

View full text Add to dashboard Cite

Following the introduction of nalidixic acid into clinical practice in the 1960s, fluoroquinolones have undergone profound structural modifications, leading to the development of numerous molecules in this class (1-3). Modifications to the quinolone structure, particularly the addition of fluorine(s) at key positions, have provided compounds with increased potency, broader spectrum of activity, and acceptable safety profiles. However, safety has been problematic in fluoroquinolone development (4-6). Several potent compounds have either been determined to be unsuitable for human use due to unacceptable toxicities, have required black box warnings on their labels, have been restricted to topical applications, or have resulted in removal from the market (7-9). Resistance development to fluoroquinolones is also becoming a significant concern among several Gram-positive and Gramnegative pathogens, including Staphylococcus aureus, Escherichia coli, and Neisseria gonorrhoeae.AZD0914 is a new orally administered spiropyrimidinetrione bacterial DNA gyrase inhibitor that demonstrates a novel mode of inhibition distinct from that of fluoroquinolones (10, 11). AZD0914 is a selective and potent inhibitor of the supercoiling and decatenation activity of DNA gyrase and topoisomerase IV, with the ability to overcome fluoroquinolone resistance by the inhibition of DNA biosynthesis through the accumulation of double-stranded cleaved DNA bound to the tetramer topoisomerase II.AZD0914 has a primary spectrum of activity that includes clinically relevant Gram-positive and fastidious Gram-negative bacterial species, including N. gonorrhoeae (12)(13)(14)(15). Published in vitro data on Chlamydia trachomatis and Chlamydia pneumoniae have shown that AZD0914 also has activity against these species (16). Its activity is maintained against strains with common fluoroquinolone resistance mutations in gyrase and topoisomerase IV within the quinolone resistance-determining region (QRDR) (12). Resistance to other key antimicrobial classes, such as ␤-lactams, macrolides, and glycopeptides, also do not diminish the activity of AZD0914. Currently, AZD0914 is being investigated in phase 2 trials for the treatment of uncomplicated N. gonorrhoeae infections (14,15).In this study, the in vitro activity of AZD0914 against key bacterial groups isolated from intra-abdominal, urinary tract, skin and soft tissue, and respiratory tract infections collected in a 2013 global surveillance survey was analyzed and compared to that of levofloxacin, moxifloxacin, and other nonfluoroquinolone compounds.(This study was presented, in part, at the 54th Interscience Conference on Antimicrobial Agents and Chemotherapy in 2014 [12].) MATERIALS AND METHODSClinical isolates (n ϭ 21,152) from hospitalized patients were collected at 169 medical centers in 39 countries distributed across North America, Latin America, Europe, Asia-Pacific, and Middle East/Africa during 2013. Isolates were obtained from specimens collected from patients with documented intra-abdominal infections...

show abstract

Levofloxacin-ResistantHaemophilus influenzae, Taiwan, 2004–2010

Cited by 48 publications

References 14 publications

Molecular Characterization of Fluoroquinolone Resistance in Nontypeable Haemophilus influenzae Clinical Isolates

Molecular Characterization of Fluoroquinolone Resistance in Nontypeable Haemophilus influenzae Clinical Isolates

Clinical Characteristics of Haemophilus influenzae at General Hospital in the Central Region of Japan

In Vitro Activity of AZD0914, a Novel Bacterial DNA Gyrase/Topoisomerase IV Inhibitor, against Clinically Relevant Gram-Positive and Fastidious Gram-Negative Pathogens

Contact Info

Product

Resources

About